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Abstract
Poor prognosis in neuroblastoma is associated with genetic amplification of MYCN. MYCN is 
itself a target of let-7, a tumor suppressor family of microRNAs implicated in numerous cancers. 
LIN28B, an inhibitor of let-7 biogenesis, is overexpressed in neuroblastoma and has been reported 
to regulate MYCN. However, here we show that LIN28B is dispensable in MYCN-amplified 
neuroblastoma cell lines, despite de-repression of let-7. We further demonstrate that MYCN 
mRNA levels in amplified disease are exceptionally high and sufficient to sponge let-7, which 
reconciles the dispensability of LIN28B. We found that genetic loss of let-7 is common in 
neuroblastoma, inversely associated with MYCN-amplification, and independently associated with 
poor outcomes, providing a rationale for chromosomal loss patterns in neuroblastoma. We propose 
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that let-7 disruption by LIN28B, MYCN sponging, or genetic loss is a unifying mechanism of 
neuroblastoma pathogenesis with broad implications for cancer pathogenesis.
Carcinogenesis involves multiple genetic and epigenetic events, yet the organizing principles 
underlying their choreography are poorly understood. MicroRNA (miRNA) deregulation is 
an important component of this landscape through both oncogenic and tumor suppressive 
functions of miRNAs1. Of these, the highly conserved let-7 family has a prominent role in 
the regulation of embryonic development and maintenance of differentiated tissues and is 
among the most abundantly expressed miRNAs. It serves as a potent tumor suppressor via 
post-transcriptional repression of multiple oncogenic mRNA targets including RAS, MYC, 
and HMGA22–4. Let-7 is downregulated in multiple tumor types and has been causally 
linked to oncogenesis1,5–8. Uncovering the mechanisms by which let-7 function is 
neutralized is therefore critical to both the fundamental understanding of cancer 
pathogenesis and novel therapies.
Several mechanisms of let-7 disruption have emerged in different contexts. First, its 
biogenesis can be suppressed by the LIN28B RNA-binding protein9; a highly conserved 
heterochronic gene implicated in cancer and reported to induce tumors in multiple mouse 
models including hepatocellular carcinoma, colon cancer, Wilms’ tumor, and 
neuroblastoma10–16. Second, competing endogenous RNAs (ceRNAs) have been proposed 
to sponge miRNAs, including let-7, diluting their activity through competition for miRNAs 
with sites common to multiple ceRNA species17–19. Third, chromosome loss is a suggested 
mechanism of let-7 disruption in cancer, as genetic deletion of let-7 is associated with 
several solid tumors1.
The neuroblastoma master oncogene, MYCN, has a 910 nucleotide long 3′UTR containing 
two let-7 binding sites which are almost perfectly conserved among land vertebrates, 
suggesting strong functional relevance20–22 (ED 1). Coding sequence mutations in 
neuroblastoma are rare23,24, whereas chromosome arm gain or loss events are common25,26. 
The most well-known chromosomal aberration is amplification of the MYCN locus, which 
occurs in ~25% of all neuroblastomas and largely defines poor prognosis27,28. Other 
common chromosomal deletions at chromosome arms 3p and 11q are inversely associated 
with MYCN-amplification. The reason for this discordance is unknown.
Here, we set out to understand the relationship between MYCN and let-7 in neuroblastoma. 
A complex relationship emerged between LIN28B activity, a novel ceRNA function of the 
MYCN 3′UTR, and let-7 genetic loss, which together present a unifying model of let-7 
suppression during neuroblastoma pathogenesis. This model provides an organizing 
principle for understanding distinct genetic patterning in neuroblastoma, with potential 
implications for cancer in general.
LIN28B and let-7 regulate the MYCN 3′UTR
LIN28B is highly expressed in human neuroblastoma and its expression correlates with 
tumor stage, rendering the LIN28B/let-7 axis an attractive target for interrogation (ED 2 a, b, 
c, d). Two recent reports concluded that this pathway plays a critical role in regulating 
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MYCN and neuroblastoma cell growth12,13. To examine the relationship between the 
MYCN transcript, let-7 and LIN28B, we first transfected non-MYCN amplified 
neuroblastoma cells with the MYCN open reading frame, with or without the 3′UTR 
carrying intact or mutant let-7 sites (fig. 1a). The full-length wildtype MYCN transcript 
produced markedly lower MYCN protein levels than the ORF-only construct. Mutation of 
the let-7 sites in the 3′ UTR partially rescued MYCN expression, implicating let-7 
modulation as an important component of MYCN post-transcriptional regulation (fig. 1b). 
Expression of LIN28B suppressed the let-7 family in non-MYCN-amplified neuroblastoma 
cells and conferred a growth advantage. LIN28B rescued expression of the wildtype 3′ UTR 
construct, demonstrating that LIN28B can support MYCN expression through let-7 
repression in the absence of MYCN amplification (ED 2e, 2f, fig. 1c). However, when we 
transfected MYCN-amplified cells with a let-7a mimic, we observed decreased MYCN 
protein levels only above 15 and 80 fold increases in cellular levels of let-7a, respectively, 
suggesting that MYCN was refractory to all but exceedingly high levels of exogenous let-7 
(fig. 1d).
LIN28B is dispensable in MYCN-amplified neuroblastoma cell lines
Next, we evaluated the previously reported LIN28B-let-7-MYCN regulatory circuit using 
published lentiviral shRNA constructs to knockdown LIN28B in MYCN-amplified 
neuroblastoma cells and observed comparable suppression of MYCN protein levels and cell 
growth (ED 3a,b). We further observed reduced xenograft tumor growth in cells expressing a 
LIN28B targeting shRNA (ED 3c). However, we did not observe an appreciable de-
repression of let-7 levels upon shRNA-mediated LIN28B knockdown, which is counter to 
the established paradigm (ED 3d). Moreover, we were unable to rescue these effects through 
overexpression of shRNA-resistant LIN28B constructs (ED 3e,f). Together, these data 
suggest that the reported effects of the shRNAs on both cell growth and MYCN protein 
levels might be due to hairpin-induced toxicities.
As an alternative approach to depleting LIN28B, we tested five small interfering RNAs 
(siRNAs) and found that four both effectively knocked down LIN28B and, as expected, de-
repressed let-7 levels (ED 4a–d). Upon extended serial siRNA transfection, we observed that 
despite robust LIN28B knockdown and strong de-repression of let-7, MYCN protein levels 
were unaffected and there was no appreciable effect on cell proliferation (ED 4e–g).
To rule out the possibility of incomplete knockdown resulting in residual LIN28B activity, 
we employed Cas9 and four distinct gRNAs targeting LIN28B (ED 4h). We observed robust 
loss of LIN28B protein with all four gRNA constructs (fig 2a,b), indicating efficient 
disruption of the locus. We did not observe appreciable loss of MYCN protein expression or 
impaired cell growth, thus corroborating our siRNA based results (fig. 2a–d). In addition, the 
let-7 family was robustly de-repressed, consistent with the existing LIN28B/let-7 paradigm 
(fig. 2e,f). These observations indicate that disruption of LIN28B has little net impact on 
MYCN-amplified neuroblastoma cells.
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MYCN is a let-7 sponge in MYCN-amplified neuroblastoma
The persistence of MYCN protein levels despite high levels of transfected let-7a or robust 
de-repression of let-7 upon LIN28B loss prompted us to explore novel mechanisms of let-7 
perturbation. We hypothesized that there might be a ceRNA in MYCN-amplified 
neuroblastoma cells that serves to sponge let-7. To identify potential ceRNAs, we performed 
poly-A selected RNA-sequencing (mRNA-seq) on MYCN-amplified (BE(2)C and Kelly) 
and non-MYCN-amplified (SH-SY5Y) cells. We then determined the relative contribution of 
let-7 target sites provided by expressed let-7 targets. Interestingly, MYCN itself was by far 
the most abundant let-7 target mRNA in both BE(2)C and Kelly cells, alone providing 
19.3% and 18.5% of the entire cellular let-7-target-site pool, respectively. In contrast, 
MYCN represented only 0.15% of the let-7-target-site pool in SH-SY5Y cells (fig. 3a). In 
fact, MYCN mRNA was the 2nd highest expressed mRNA in both BE(2)C and Kelly cells as 
opposed to the 5409th highest in SH-SY5Y, demonstrating an exceptionally high MYCN 
mRNA level in MYCN-amplified cells (>100-fold increase; fig. 3b). Other multiple-let-7-
site mRNAs such as HMGA2, IMP1, and ARID3B were expressed at much lower levels, 
together suggesting that MYCN mRNA might itself be the sponge (ED 5a). This expression 
pattern was validated by qPCR in a panel of additional cell lines (ED 5b).
CeRNA relationships were initially defined in part by similar expression levels between 
RNAs with similar 3′UTRs18,29. Two recent reports have refined this original precept, 
suggesting that for a given miRNA family, the miRNA: mRNA-target ratio is a major 
determinant of how effectively a ceRNA can impact the function of a miRNA family. At low 
ratios, miRNAs are sensitive to moderate levels of ceRNAs, whereas highly expressed 
miRNAs with high ratios are difficult to sponge, requiring very high levels of ceRNA30,31. 
We therefore assessed total copies per cell of both MYCN mRNA and the let-7 family in 
BE(2)C and Kelly cells through quantified mRNA-seq and small-RNA sequencing (sRNA-
seq) (ED6).
We calculated 13,255 and 10,615 MYCN mRNA copies per BE(2)C and Kelly cell, 
respectively, resulting in 26,511 and 21,231 let-7 target sites provided by MYCN (fig. 3c 
upper panel). In stark contrast, there were only 31 MYCN transcripts per SH-SY5Y cell. 
Quantification of the let-7 family in BE(2)C and Kelly cells yielded 7,259 and 1,952 total 
let-7 molecules per cell (fig. 3c lower panel), and MYCN-let-7-site: let-7 miRNA ratios of 
3.65 and 10.88, respectively. These ratios satisfy the tenets of the ratio-based ceRNA model 
and do so as the result of a single amplified mRNA. Interestingly, let-7a was the most highly 
expressed let-7 family member in both cell types, accounting for over half of all let-7 
molecules. These observations were confirmed by spike-in qPCR based quantification of 
both MYCN and let-7 (ED 7a, b). Even upon LIN28B knockout, the MYCN-let-7-site: let-7 
ratio is 1.35 in BE(2)C and 1.78 in Kelly, which remain favorable for ceRNA activity (ED 
7c).
To test the capacity of MYCN mRNA to serve as a let-7 sponge, we co-transfected BE(2)C 
cells with a series of luciferase constructs containing the 3′UTRs of several representative 
let-7 targets and control or MYCN ORF targeting siRNA (ED 8a,b). Luciferase ratios of all 
constructs save for empty vector controls and the let-7-site-mutated MYCN-3′UTR, were 
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significantly reduced by either MYCN knockdown or let-7a transfection (fig. 3d), suggesting 
that the endogenous MYCN-3′UTR sponges steady-state levels of let-7. We then tested the 
sufficiency of the MYCN-3′UTR to de-repress let-7 targets through sponging of a let-7a 
mimic. We co-transfected the above luciferase reporter constructs with chimeric 
RFP:MYCN-3′UTR constructs and assayed luciferase activity (ED 8c,d). Let-7 target 
constructs were rescued when co-transfected with wildtype but not let-7-site-mutant 
MYCN-3′UTR (ED 8e). In addition, exogenous MYCN-3′UTR was sufficient to enhance 
MYCN protein expression itself in SK-N-AS cells (ED 8f).
We next tested if endogenous let-7 targets are sponged. Upon MYCN knockdown, protein 
levels of DICER1, HK2, IMP1, and LIN28B were reduced, while neither mRNA nor let-7 
levels were significantly changed (ED 8a, b, c). Concurrent let-7 inhibition rescued 
expression of the four targets, supporting post-transcriptional suppression through let-7 upon 
MYCN knockdown that is consistent with MYCN mRNA serving as a let-7 sponge (ED 8a). 
Further, these targets were not reduced at the protein level upon LIN28B knockout, which is 
consistent with this model (ED 8d).
Lastly, we analyzed global let-7 target expression in response to depletion of the endogenous 
MYCN 3′UTR. To specifically assess the role of the 3′UTR, we transfected BE(2)C cells 
expressing a MYCN ORF transgene with a MYCN 3′UTR-targeting siRNA (fig. 3e). While 
we did not see a global reduction of let-7 targets as a whole (ED 9e), we did observe 
significantly lower expression of let-7 targets with 3 or more total sites or more than one 
8mer let-7 site in their 3′ UTRs, which together define the most sensitive let-7 targets32,33 
(fig. 3f). Given the regulation of the MYCN 3′ UTR by multiple miRNAs34 and unknown 
kinetics of how let-7 activity is restored after the removal of a ceRNA, we further challenged 
siCon and siMYCN cells with a modest amount of let-7a mimic, increasing cellular let-7 
levels approximately 8 fold (ED 9f). We then observed significantly reduced expression 
across all categories of let-7 targets in siMYCN cells, consistent with increased sensitivity to 
let-7 in the absence of the MYCN 3′ UTR. (fig. 3g, ED 9g).
Let-7 chromosomal loss in neuroblastoma
While neuroblastoma has a low mutation rate, chromosome arm gain and loss is 
frequent23,24. Two of the most common chromosomal losses in neuroblastoma, chromosome 
arm 3p (Chr3p, ~33% incidence) and Chr11q (~45% incidence), often occur together and 
seldom with MYCN-amplification23,35,36 (fig. 4a, ED 10). Upon analysis of Chr3p and 
Chr11q, we noted that the Chr3p-loss smallest region of overlap (SRO) spans from 3p25.3 to 
3p14.337, placing let-7g within the SRO and resulting in its loss whenever Chr3p is lost. In 
addition, the most common breakpoint of Chr11q immediately proximal to the let-7a2 locus, 
resulting in loss of let-7a2 in virtually all Chr11q deletions35 (fig. 4b). Moreover, loss of 
Chr11q in neuroblastoma results in lower overall let-7a levels despite loss of only one of 
three distinct let-7a loci38. These observations suggest that let-7 genetic disruption may be 
selected for in neuroblastoma.
A model in which amplified MYCN sequesters mature let-7 in would predict that selective 
pressure to genetically lose let-7 might be relieved in MYCN-amplified disease. Chr3p 
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(let-7g) and Chr11q (let-7a2) loss patterns are indeed consistent with such a model. To 
investigate whether the extended let-7 family (fig. 4b) follows this loss pattern, we expanded 
our analysis to all eight let-7 genetic loci in 202 neuroblastomas by array comparative 
genomic hybridization (aCGH). We created a heat-map of copy number (CN) estimates for 
each miRNA locus to compare MYCN-amplified CN values to non-amplified and observed 
a significant CN difference for six let-7 loci (fig. 5a, 5b upper panel). At least one let-7 
family member was lost in 63.4% of non-amplified tumors and in only 16.7% of amplified 
(fig. 5b upper panel), resulting in average let-7 CN changes of −1.94 and −0.36 per tumor, 
respectively (fig. 5b lower panel). This pattern of CN loss for let-7 is distinct from the 
unrelated miR-103a family (fig. 5b), suggesting that the let-7 pattern is not reflective of 
general chromosomal patterning.
Let-7a2, let-7f2, and let-7g were most commonly lost, whereas let-7a3/7b and let-7i were 
not significantly lost in any tumor subset. We reasoned that loss frequency might relate to 
initial expression level. To interrogate this possibility, we used publicly available sRNA-seq 
data to examine the relative expression levels of mature let-7 in twelve distinct primary and 
tumor cell lines that have intact let-7 loci (ED 10b). We observed that let-7a, let-7f, and 
let-7g are present at higher relative levels than other let-7 family members, which mirrors 
the CN loss patterns in non-MYCN-amplified neuroblastoma (fig. 5c). MiR-100, the 
miRNA-cluster partner of let-7a2, is more highly expressed than most let-7s and their cluster 
partners, suggesting that the bulk of the let-7a reads may come from the let-7a2/miR-100 
locus (fig. 5c).
A limitation of sRNA-seq is that it cannot distinguish between loci that produce the same 
mature miRNA. Let-7 family members are coordinately transcribed as part of larger host 
transcripts (HTs) from which they are then processed, which allows for locus-specific 
expression analysis7,39,40 (ED 10c). We therefore analyzed relative expression levels of let-7 
HTs in six primary and tumor cell lines. HT levels for let-7a2, 7f2, and 7g were significantly 
higher than other let-7 HTs (ED 10d, fig. 5d), reflecting the pattern of most frequent locus 
loss in non-amplified disease. In addition, analysis of existing human neuroblastoma 
mRNA-seq and microarray datasets revealed lower expression of the let-7a2, let-7f2, and 
let-7g HTs in non-amplified vs. MYCN-amplified tumors, which is consistent with observed 
patterns of CN loss in our aCGH dataset (fig. 5e, ED 10e). Further, MYCN and let-7 
expression are negatively correlated in non-amplified disease, underscoring the importance 
of let-7 disruption in the absence of the MYCN ceRNA34. These data may collectively 
explain both preferential loss of certain let-7 loci and common patterns of chromosomal loss 
in neuroblastoma.
Further underscoring the significance of let-7 suppression is the observation that non-
MYCN-amplified neuroblastoma patients had significantly worse overall survival (OS) if 
there was a let-7 CN loss event (fig 5f top panel). In the rare case where MYCN-
amplification and let-7 CN loss occurred together, OS was dramatically reduced relative to 
the already poor-prognosis of MYCN-amplification (fig. 5f bottom panel), suggesting a 
deleterious synergy between two powerful but typically exclusive mechanisms of functional 
let-7 disruption.
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Of note, one of the tumors in the aCGH dataset had genetic amplification of LIN28B 
(CN=23, fig. 5a). This tumor patterned closely with MYCN-amplified tumors with regard to 
net let-7 loss and tumor stage (IV) despite being 2n for MYCN. This may represent a case 
where LIN28B significantly contributed to neuroblastoma through let-7 suppression similar 
to the reported mouse model of murine-Lin28b driven neuroblastoma12.
Discussion
The known functionality of LIN28B, together with the patterns of genetic deletion of let-7 
and amplified MYCN ceRNA (aceRNA) activity described here establish that 
neuroblastoma employs multiple mechanisms to neutralize let-7, placing let-7 disruption at 
the center of neuroblastoma pathogenesis. We thus propose that let-7 biogenesis and 
function are targeted in neuroblastoma by several disparate mechanisms: high frequency 
genetic loss, LIN28B activity, or MYCN aceRNA (ED 10f). This model has implications for 
our understanding of neuroblastoma pathogenesis, disease modeling, and the rational design 
of therapeutic strategies, and may represent a more general feature of human cancer.
First, our model offers a plausible explanation for the uniquely high MYCN mRNA levels in 
amplified neuroblastoma, which enables both robust expression of MYCN protein and 
adequate copies of a ceRNA sufficient to impair the function of a highly expressed miRNA 
like let-7. Questions may remain about whether an observed >100 fold increase in MYCN 
mRNA, which increases the total let-7 target-sites across the cellular pool of mRNAs by 
only approximately 25%, is sufficient to mediate a ceRNA effect on let-7. However, our 
functional data based on loss of the MYCN 3′UTR, including candidate reporter analysis of 
let-7-site-containing 3′ UTRs and global let-7-target mRNA-seq analysis (fig. 3d–g), 
suggest that MYCN mRNA may be a preferred target that in abundance can sequester and 
impair let-7. Further, in tumors lacking MYCN amplification, our model suggests that 
selective pressure to disrupt let-7 explains the well known, yet unresolved, patterns of 
MYCN-amplification-independent chromosome 3p and 11q loss. AceRNA function of 
MYCN mRNA also accounts for the dispensability of LIN28B in MYCN-amplified cell 
lines, suggesting that LIN28B may serve a redundant let-7 suppressive role.
Our findings suggest that highly expressed 3′UTRs contribute to miRNA deregulation in 
cancer, and therefore both coding and non-coding functions of oncogenic mRNAs should be 
considered in animal tumor modeling. For example, both the TH-MYCN and LSL-
MYCN;Dbh-iCre models of murine neuroblastoma overexpresses the MYCN open reading 
frame and lack 3′UTRs. Notably, the TH-MYCN model has similar patterns of let-7a2, 
let-7f2, and let-7g genetic loss as non-amplified human disease and both models broadly 
downregulate the let-7 family34,41, further suggesting that let-7 disruption is important even 
in the presence of MYCN protein expression. Moreover, a recent report demonstrates that 
high level expression of the BRAF pseudogene, which contains a functional 3′UTR but does 
not encode a protein, is sufficient to induce lymphoma in mice42. Consequently, full-length 
mRNA transgenes may yield more accurate genetic modeling of human tumors in animals.
Lastly, our model establishes let-7 restoration as a key therapeutic goal in neuroblastoma. 
There are few neuroblastoma specific therapies, and attempts to directly target MYCN have 
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met with little success, despite efforts spanning the last 20 years25,26,43. The fact that 
MYCN mRNA has such a strong functional connection to let-7 exposes a valuable 
opportunity to target MYCN itself and provides hope of delivering disease specific therapy 
to the worst prognostic class of neuroblastoma.
We show here that disparate modes of let-7 suppression are selectively and inversely related 
in neuroblastoma. Given that both oncogenic amplification and disruption of let-7 biogenesis 
appear to play central roles in multiple cancer types15,44–47, our model may provide a novel 
organizing principle by which to consider and interrogate genetic events in a broad range of 
tumors.
Methods
Cell culture
BE(2)C (ATCC #CRL-2268), PA-1 (ATCC #CRL-1572), IMR90 (ATCC #CRL-186), SK-N-
AS (ATCC #CRL-2137), SH-SY5Y (ATCC #CRL-2266), 293T(ATCC #11268), SK-N-DZ 
(ATCC #CRL-2149) and Kelly cells (Sigma #92110411-1VL) were maintained in 1:1 
DMEM/F12:MEM media with 10% inactivated fetal calf serum, 1ug/ml penicillin, and 
1U/ml streptomycin. All cell lines were purchased for the purposes of this study, are not 
among commonly misidentified cell lines (per ICLAC), and tested negative for mycoplasma 
contamination.
Plasmids
Turbo-RFP, LIN28B, and MYCN(ORF) cDNAs were subcloned into the pcDNA3.1 
expression vector (Invitrogen). The MYCN 3′UTR was cloned from BE(2)C cDNA and 
subcloned into pcDNA3.1:MYCN to create pcDNA3.1:MYCN/3′UTR. ShRNA-resistant-
LIN28B and pcDNA3.1:MYCN/3′UTR-let-7-site-mutant vectors were made using the 
QuikChange© site-directed-mutagenesis kit (Stratagene) on pcDNA3.1:LIN28B and 
pcDNA3.1:MYCN/3′UTR constructs, respectively. Wildtype and mutant MYCN 3′UTRs 
were subcloned into pcDNA3.1:RFP and psiCHECK2 to create pcDNA3.1:RFP/
MYCN-3′UTRwt and pcDNA3.1:RFP/MYCN’-3′UTRmut as well as 
psiCHECK2:MYCNwt and psiCHECK2:MYCNmut. pIS1:DICER1, pIS1:IGF2BP1, and 
pIS1:Hmga2 were gifts from David Bartel1,2 (Addgene plasmids #21649, #21639, and 
#14785). psiCHECK2-8x-let-7 was a gift from Yukihide Tomari3 (Addgene plasmid 
#20931).
siRNA/let-7 mimic transfections
BE(2)C and Kelly cells were reverse transfected using Lipofectamine 2000© (Life 
Technologies) into 6 well plates using the appropriate siRNA or miRNA mimics (described 
below). Cells were harvested at time-points described for analysis by western or qPCR. 
Growth assays were performed similarly, but in 96 well plates followed by time-point 
specific BrdU growth assay. Global let-7 target analysis: BE(2)C:MYCN-ORF cells co-
transfected with control or MYCN-3′UTR-2 siRNA and either control or let-7a miRNA 
mimic were harvested 48 hours post transfection. Control siRNA (Life Technologies 
#439846). LIN28B siRNAs: ORF1 (Life Technologies #4392420, ID:s52479), ORF2 (Life 
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Technologies #4392420, ID:s52477), 5′UTR (GE Dharmacon Custom LIN28B-
NM_001004317 Duplex siRNA, ON-TARGET Plus, sense: 5′-ACU GGA GAG AGG AGA 
GAA AUU-3′, antisense: 5′-UUU CUC UCC UCU CUC CAG UUU-3′), 3′UTR-1 (GE 
Dharmacon #J-028584-12-0020), 3′UTR-2 (GE Dharmacon Custom LIN28B-
NM_001004317 Duplex siRNA, ON-TARGET Plus, sense: 5′-CAA CAG UGA UUG UGA 
GAA UUU-3′, antisense: 5′-AUU CUC ACA AUC ACU GUU GUU-3′). MYCN siRNAs: 
ORF-1 (Life Technologies #4392420, ID:s9135), ORF-2 (Life Technologies #4392420, 
ID:s9134). Control miRNA mimic (Life Technologies #4464059). let-7a miRNA mimic 
(Life Technologies #4464066, ID:MC10050), let-7a inhibitor (Life Technologies #4464084, 
ID:MH10050).
Luciferase Assays
For the MYCN 3′UTR loss of function assays, BE(2)C cells were reverse co-transfected 
using Lipofectamine 2000© in quadruplicate into 96-well plates with the appropriate 
luciferase vector and either control siRNA, MYCN siRNA or let-7a mimic. 60 hours post-
transfection, luciferase activity was assayed using the Dual Luciferase© Reporter Assay 
System (Promega). For the MYCN 3′ UTR gain of function assays, 293T cells were seeded 
into 96-well plates in quadruplicate and transfected using Lipofectamine 2000© the 
following day with the appropriate luciferase vector, MYCN 3′UTR overexpression vector, 
and either control miRNA mimic or let-7a mimic. Luciferase activity was measured 24 
hours post-transfection as described above.
Immunohistochemistry
Performed on human tumor tissue sections as previously described4 using anti-LIN28B 
antibody (Cell Signaling #4196) at a 1:400 dilution. Patient samples were obtained through 
Boston Children’s Hospital IRB-CRS08-09-0429-2; Immunohistochemical and Molecular 
Analysis of Pediatric Tumors and consent was obtained from all subjects.
Western blotting
Western blots were performed with antibodies against LIN28B (Cell Signaling #4196), 
LIN28A (Cell Signaling #3978), MYCN (Santa Cruz Biotechnology #sc-53993), DICER1 
Santa Cruz #sc-30226), HK2 (Cell Signaling #2867S), IMP1 (Cell Signaling #2852S), tRFP 
(Origene #TA150061), β-TUBULIN (Cell Signaling #2146), and β-ACTIN (Santa Cruz 
Biotechnology #sc-8342).
BrdU growth assay
5000 cells per well were plated on a 96 well plate in quadruplicate for each of three 
independent experiments. Cell proliferation was assayed relative to day zero using the BrdU 
Cell Proliferation Assay Kit (Cell Signaling #6813) according to manufacturers protocol 
following two hour incubation with BrdU.
qPCR
Total RNA was isolated from cells using Trizol© reagent (Life Technologies). For mRNA 
analysis, cDNA was prepared from 1ug RNA using Superscript II© Reverse Transcriptase 
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(Life Technologies) and random hexamers. 20ng of cDNA was then used for qPCR with the 
SYBR© Select Master Mix (Life Technologies). mRNA primers: LIN28B (fwd: GAG TCA 
ATA CGG GTA ACA GGA C, rev: CAC CAC AGT TGT AGC ATC TAT CT) MYCN-1 
(fwd: CGA TTC AGA TGA TGA AGA TGA TGA AG, rev: GAC AGC CTT GGT GTT 
GGA), IGF2BP1 (fwd: CAG TCC AAG ATA GAC GTG CAT AG, rev: CTC AGG GTT 
GTA AAG GGT AAG G), DICER1 (fwd: CTC CTA CCA CTA CAA TAC TAT CAC T, rev: 
GGT CTT CAT AAA GGT GCT TGG T), β-ACTIN (fwd: GAC CCA GAT CAT GTT TGA 
GAC C, rev: CGT AGC ACA GCT TCT CCT TAA T), HMGA2 (fwd: CTG CTC AGG 
AGG AAA CTG AAG, rev: CAC TAA ACC TGG GAC TGT GAA G), ARID3B (fwd: 
CAA GCA GAA TGG TGG TTT GG, rev: ATG GAT GTG GGC AGG TTT AG). For let-7 
analysis, cDNA was prepared using 20ng total RNA and the Taqman© microRNA Reverse 
transcription kit (Life Technologies). 2ng cDNA was then used for qPCR with the Taqman© 
Universal PCR Master Mix (Life Technologies). Taqman© microRNA Assays used (Catalog 
#:4427975): let-7a (ID:000377), let-7b (ID:002619), let-7c (ID:000379) let-7d (ID:002283), 
let-7e (ID:002406), let-7f (ID:000382), let-7g (ID: 002282), let-7i (ID:002221), miR-98 (ID:
000577), U47 control microRNA Assay (ID:001223). For both mRNA and let-7 expression 
analysis, relative expression was determined using the ΔΔCT method, unless otherwise 
noted.
qPCR CPC Analysis
Total RNA per cell was determined by RNA harvest yield from 1.5 x 106 cells. For MYCN 
mRNA copies per cell, cDNA was prepared using 200ng total RNA per cell type and from a 
dose curve of the synthetic MYCN-3′UTR-RNA-fragment (Integrated DNA Technologies) 
with Superscript III© Reverse Transcriptase (Life Technologies) and a MYCN-gene-specific 
primer (MYCN-2 rev). 10% of the cDNA reactions were then used for qPCR as described 
above. Linear regression analysis was performed on MYCN-3′UTR-RNA-fragment-sample 
CT values to determine the copies per reaction in the cell samples. MYCN mRNA copies 
per cell was then calculated based on the total RNA per cell previously determined. 
Synthetic MYCN-3′UTR-RNA-fragment sequence: (5′-TTC CTA GCC TGT TTC TTC 
CTG TTA ATG TAT TTG TTC ATG TTT GGT GCA TAG AAC TGG GTA AAT GCA 
AAG TTC TGT GTT TAA TTT CTT CAA AAT GTA TAT ATT TAG TGC TGC ATC TTA 
TAG CAC TT -3′). MYCN-2 qPCR Primers (fwd: CCT AGC CTG TTT CTT CCT GTT A, 
rev: GTG CTA TAA GAT GCA GCA CTA AAT). A similar strategy was used to determine 
let-7 copies per cell. Synthetic let-7 RNA molecules for each let-7 family member 
(Integrated DNA Technologies) were used in dose curves for cDNA reactions for each let-7. 
cDNA was prepared as described above, and 10% of cDNA reactions were used for qPCR as 
described above. Linear regression analysis of the synthetic-let-7 qPCR CT values and total 
RNA per cell values were used to calculate copies per cell for each let-7 family member.
RNA-Seq analysis
Copies per Cell Analysis: Sequence reads were aligned to the human transcriptome using 
HISAT version 0.1.65. The transcriptome file used for polyA-RNA based libraries consisted 
of protein-coding and ncRNA sequences downloaded from ENSEMBL (release 80) ftp://
ftp.ensembl.org/pub/release-80/fasta/homo_sapiens/, as well as the ERCC control 
sequences. The transcriptome file used for short-RNA based libraries consisted of mature 
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microRNA sequences downloaded from mirBase (release 21: ftp://mirbase.org/pub/
mirbase/), in addition to the synthetic short RNA spike in oligonucleotides (Small RNA 
Spikes: LET7A2-5′SCR:/5Phos/rGrA rArGrA rUrGrU rGrGrU rGrUrU rGrUrA rUrArG 
rUrU, LET7I-5′SCR: 5′Phos-rGrG rUrArG rArUrA rGrUrU rGrUrU rGrUrG rCrUrG 
rUrU, MIR-NEG: 5′Phos-rUrU rArCrG rUrCrG rUrCrG rCrGrU rCrGrU rUrArU rU, 
MIR17-5′SCR: 5′Phos-rArU rCrGrC rCrUrG rArUrA rArArG rUrGrC rArGrG rUrArG, 
JP_MIR-NEG DH1: 5′Phos-rUrC rArCrA rArCrC rUrCrC rUrArG rArArA rGrArG 
rUrArG rA, JP_MIR-NEG DH2: 5′Phos-rUrU rGrUrA rCrUrA rCrArC rArArA rArGrU 
rArCrU rG)6. To estimate transcript abundances, we applied Salmon version 0.3.27 to the 
aligned reads and summarized transcript abundances into gene-level expression levels by 
summing all transcript expression levels mapping to the same gene. Gene-to-transcript 
mappings, and transcript type annotations were downloaded also from ENSEMBL (ftp://
ftp.ensembl.org/pub/release-80/gtf/homo_sapiens/). Unless otherwise stated, all RNA-Seq 
data is presented is Log10(1+TPM), which we refer to as Log(TPM) henceforth. In order to 
estimate the absolute copy number of transcripts per cell, we performed linear regression of 
the spike-in oligonucleotides concentration (Log10) on the Log(TPM) using the lm function 
in R for each sample. Using the slope and intercept estimated by this approach, we 
calculated the copies per cell of endogenous mRNA by determining the number of 
transcripts (based on Log(TPM) values) present in the total ng RNA used for library 
preparation. We then determined molecules per cell based on pre-determined pg RNA per 
cell. Global let-7 target analysis: polyA-selected mRNA sequencing reads were processed as 
above, with no spike in RNAs used. RNA-seq datasets are available under GEO reference 
series GSE81500: (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81500).
Supplemental Methodology: spike controlled quantification of small RNA—
Through comparison to three miRNA spike-ins, including let-7-specific 5′-end-scrambled 
let-7a and let-7i spikes, we sought to minimize the effects of secondary structure bias known 
to exist during sRNA-seq library preparations, which can have significant effects on the 
relative efficiency of reads produced between different microRNAs6 (ED 6). A total of six 
synthetic spikes were used. Disparate reads per million observed among the equimolar small 
RNA spikes (i.e. the miR-Neg, LET7A2, LET7I spikes have much higher read counts than 
equimolar MIR17, miRNegDH1, and miRNegDH2 spikes) demonstrate both the need to use 
spikes similar to the miRNA-of-Interest to accurately determine copies per cell and the risk 
inherent in using a single spike to determine copies per cell for all miRNAs. The use of 
multiple miRNA-specific spikes improves upon previous miRNA quantification strategies 
using a single control miRNA to quantify all miRNAs8 by limiting potential disparate read 
efficiencies between a single spike and the miRNA of interest. Difficulty in calculation of 
relative expression of disparate miRNAs within a single dataset due to such variable read 
efficiencies can therefore be mitigated through the use of spike-ins that closely resemble 
each miRNA of interest.
CRISPR/Cas9
Cas9/gRNA co-expressing lentiviral constructs (lentiCRISPRv2) were generated and 
lentiviral particles were produced as previously described9,10, using protocols and gRNA 
design tools from http://www.genome-engineering.org. Puromycin selection began twenty 
Powers et al. Page 11
Nature. Author manuscript; available in PMC 2017 January 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
four hours after lentiviral infection of BE(2)C and Kelly cells. Experiments were typically 
completed within three weeks of initial infection. Oligos used for gRNA cloning: LIN28B 
exon 2: (CAC CGC ATC GAC TGG AAT ATC CAA G, AAA CCT TGG ATA TTC CAG 
TCG ATG C). LIN28B exon 3.1: (CAC CGC AGA GCA AAC TAT TCA TGG A, AAA 
CTC CAT GAA TAG TTT GCT CTG C). LIN28B exon 3.2: (CAC CGA ATG ATT ACC 
TAT CTC CCT T, AAA CAA GGG AGA TAG GTA ATC ATT C). LIN28B exon 4: (CAC 
CGC CTT GTA GAT GCT ACA ACT G, AAA CCA GTT GTA GCA TCT ACA AGG C). 
Cas9/gRNA constructs: lentiCRISPRv2, lentiCRISPR:EGFPsgRNA-1, and 
lentiCRISPR:EGFPsgRNA-2, were gifts from Feng Zhang9,10 (Addgene plasmids #52961, 
#51760, and #51761).
shRNA
Lentiviral particles were prepared as previously described4. pLKO.1 short hairpin expression 
constructs (Sigma Mission shRNA): LIN28B shRNAs (sh1: TRCN0000144508, sequence: 
5′-CCTGTTTAGGAAGTGAAAGAA-3′; sh2: TRCN0000122599, sequence: 5′-
GCCTTGAGTCAATACGGGTAA-3′). Control vector (SHC001:no insert).
Xenografts
BE(2)C and SK-N-DZ cells were infected with either SHC001 or TRCN0000122599 pLKO.
1 lentivirus, then puromycin selected for 48hrs. 1.5E6 infected cells were injected 
subcutaneously into female Rag2 knockout (c57bl/6, 8 weeks old) immune deficient mice. 
Three weeks post injection, mice were sacrificed and tumors were removed and weighed. 
This procedure is approved by the Boston Children’s Hospital Institutional Animal Care and 
Use Committee under protocol #15-12-3071R, which limits xenograft tumor size to less than 
2.0cm.
Array Comparative Genome Hybridization (aCGH) analysis
Preparation of the 202 neuroblastoma aCGH dataset has been previously described11,12. 
MicroRNA-containing loci were analyzed for gain or loss as previously described13. 
Statistical significance between MYCN-amplified and non-amplified tumors was determined 
using t test with Welch’s adjustment on original copy number values. Kaplan-Meyer curve 
generation and analysis was done using GraphPad Prism software.
ENCODE RNA-Seq datasets
Mature let-7 expression data for 12 cell types was obtained from whole cell small-RNA-Seq 
ENCODE/CSHL datasets and let-7 host transcript expression data from 6 cell types was 
obtained from RNA-seq ENCODE datasets on the UCSC Genome Browser14 (http://
genome.ucsc.edu/). Expression levels were determined relative to let-7c and let-7c host 
transcript levels, respectively.
R2 Database
Human neuroblastoma patient microarray and RNA-seq datasets were obtained from the R2: 
microarray analysis and visualization platform (http://r2.amc.nl) and analyzed using 
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GraphPad Prism software. Significance was determined by t test with Welch’s adjustment. 
Datasets used: Kozak (GEO ID: GSE45547), SEQC (GEO ID: GSE62564)
Statistical analysis
Unless otherwise noted, all experiments were performed at least three times independently. 
Statistical tests used are identified in each figure legend. P-values of less than 0.05 were 
considered significant.
Extended Data
Extended Data 1. MYCN is a highly conserved let-7 target
(a) Schematic of human MYCN ORF and 3′UTR, indicating let-7 sites 1 and 2 and their 
approximate location. (b) Predicted base pairing patterns of let-7a, let-7f, and let-7g with 
MYCN let-7 sites #1 and #2. A–G base pairs, common in RNA, are represented by (*). (c) 
Alignments of let-7 sites 1 and 2 in 100 vertebrate MYCN 3′UTRs (ENCODE).
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Extended Data 2. LIN28B expression and function in neuroblastoma
(a) MYCN, LIN28B, and LIN28A mRNA expression levels in neuroblastoma (n = 649, 
Source Data ED) (b) Immunoblot for indicated proteins in human embryonic carcinoma 
cells (PA1), normal human fibroblasts (HF), SK-N-SH (SH), SK-N-AS (AS), SK-N-F1 (F1), 
BE2C (BE), SK-N-DZ (DZ), Kelly (Ke), and human chronic myeloid leukemia cells (K5). 
For gel source data, see Supplemental Figures. (c) Representative LIN28B 
immunohistochemical staining of human neuroblastoma by stage (left panel), percent 
LIN28B positive neuroblastoma by disease stage (right panel). GNB = 
ganglioneuroblastoma. (n = 36) (d) LIN28B expression by neuroblastoma stage (n = 64, 
Source Data ED). (e) Immunoblot for LIN28B in inducible LIN28B SH-SY5Y cells and 
GFP or LIN28B expressing SK-N-AS cells (left panels) and corresponding qPCR analysis 
of relative let-7 family levels (right panel), (mean plus s.e.m. of three independent 
experiments shown). (f) Relative growth rate (BrdU incorporation, right panel) of SH-SY5Y 
and SK-N-AS neuroblastoma cells from d (*p<0.05, n = 3 independent experiments).
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Extended Data 3. Short hairpin knockdown of LIN28B in neuroblastoma
(a) Immunoblot for indicated proteins MYCN and LIN28B in MYCN-amplified cells 
infected with LIN28B targeting lentiviral shRNAs. For gel source data, see Supplemental 
Figures. (b) Cell proliferation analysis of cells described in a. (n = 3 independent 
experiments) (c) Average tumor size of human-mouse subcutaneous xenograft tumor 
analysis three weeks post injection of 2x106 cells infected with a LIN28B targeting lentiviral 
shRNA. (n = 6 mice for BE(2)C, n = 3 mice for SK-N-DZ, Supplemental Figures, Source 
Data ED). (d) qPCR analysis of let-7a, let-7b, and let-7i levels in cells described in a. (mean 
plus s.e.m. of three independent experiments shown) (e) Cell proliferation analysis of 
BE(2)C cells stably expressing red fluorescence protein (RFP), FLAG-tagged LIN28B ORF, 
or shRNA resistant FLAG-tagged LIN28B (LIN28B shRes) infected with LIN28B lentiviral 
shRNAs targeting the LIN28B 3′UTR (ShL28B-UTR) or the LIN28B open-reading frame 
(ShL28B-ORF). Cell counts were performed 7 days after lentiviral shRNA infection. (mean 
plus s.e.m. of three independent experiments shown) (f) Immunoblot for indicated proteins 
in cells described in e. For gel source data, see Supplemental Figures.
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Extended Data 4. Small interfering RNA knockdown of LIN28B in neuroblastoma
(a) Schematic of approximate siRNA target sites within the LIN28B mRNA. (b) qPCR 
analysis of LIN28B mRNA levels in BE(2)C cell 48 hours after transfection with the 
indicated LIN28B targeting siRNAs. (mean of two independent experiments shown) (c) 
Immunoblot analysis of LIN28B in cells from a. For gel source data, see Supplemental 
Figures. (d) qPCR analysis of indicated let-7 levels in cells from a. (mean of two 
independent experiments shown) (e) Immunoblot analysis of MYCN and LIN28B in serially 
transfected MYCN-amplified cells for 6 or 9 days. Identical transfections were performed of 
days 0, 3, and 6. For gel source data, see Supplemental Figures. (f) Day 9 qPCR analysis of 
the let-7 family in the cells from a. (n = 3 independent experiments, mean plus s.e.m. shown) 
(g) Cell growth analysis of day 0 to day 6 cells from a (BrdU incorporation, n = 3 
independent experiments, mean plus s.e.m. shown). (h) Lentiviral CRISPR-Cas9/LIN28B 
gRNA strategy targeting LIN28B at four distinct exon/intron junctions used in b–g.
Extended Data 5. Relative levels of let-7 targets in neuroblastoma
(a) mRNA-seq let-7 target table (as percent let-7 target site pool) (b) qPCR analysis of 
indicated let-7 targets in neuroblastoma cells, PA1 embryonic carcinoma cells (EC), and 
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normal human fibroblasts (hFib). Expression relative to β-ACTIN (ΔCT method) (mean of 
two biologic replicates shown).
Extended Data 6. Heat map of let-7 and small RNA spike reads
Heat map of three BE(2)C and three Kelly sRNA-seq samples depicting the relative reads 
per million of the let-7 family, miR-17, and the six small RNA spikes added in equimolar 
amounts per sample (spikes miR-Neg, LET7A2, and LET7I were used to determine let-7 
copies per cell from the small RNA sequencing dataset). (RPM = reads per million).
Extended Data 7. qPCR quantification of MYCN and let-7 copies per cell
(a) Total let-7 sites per cell provided by MYCN mRNA in BE(2)C, Kelly, normal human 
fibroblasts (NHF), and embryonic carcinoma cells (EC) (mean plus s.e.m. of 3 biologic 
replicates shown). (b) Total let-7 copies per cell in cells from a, presented as stacked graphs 
of all let-7 family members (mean of 3 biologic replicates shown). (c) Total let-7 CPC in 
wildtype or LIN28B knockout BE(2)C and Kelly cells, presented as stacked graphs of all 
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let-7 family members (values derived from let-7 CPC in b and average let-7 fold change 
described in fig. 2f and 2g).
Extended Data 8. Luciferase reporter and gain of function constructs
(a) Luciferase constructs used in the luciferase assays in fig. 3d and ED 8e. (b) Schematic of 
the luciferase transfection protocols used in Figure 3d. (c) Schematic of the luciferase 
protocol used in ED 8e. (d) pcDNA3.1 constructs used in ED 8e, 8f. (e) Top panel: Relative 
luciferase ratio in 293T cells co-transected with the indicated 3′UTR luciferase and 
pcDNA3.1 vectors in the presence of either control miRNA or let-7a mimic. Bottom panel: 
Relative luciferase ratio in 293T cells co-transected with the indicated 3′UTR luciferase and 
pcDNA3.1 vectors in the presence of either a control miRNA or let-7a mimic. Mean of four 
independent experiments plus s.e.m. shown (*p<0.05 relative to E.V., unpaired t-test) (f) 
Immunoblot analysis of MYCN in SK-N-AS cell stably expressing a MYCN ORF+3′UTR 
transgene and transfected with the indicated pcDNA3.1 vector. For gel source data, see 
Supplemental Figures.
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Extended Data 9. MYCN mRNA sponges let-7
(a) Immunoblot analysis of indicated proteins in BE(2)C cells transfected for 2.5 days with 
control, MYCN-1 (M1), or MYCN-2 (M2) siRNA and either control microRNA or let-7a 
inhibitor. For gel source data, see Supplemental Figures. (b) qPCR analysis of DICER1, 
HK2, IMP1, LIN28B, and MYCN in cells transfected as in a. (c) qPCR analysis of let-7a, 
let-7b, and let-7i in BE(2)C cells transfected for 2.5 days with control siRNA, siM1 or siM2. 
(n = 3 independent experiments, mean plus s.e.m. shown) (d) Immunoblot analysis of 
indicated proteins in cells infected with indicated Cas9-gRNA lentivirus. For gel source data, 
see Supplemental Figures. (e) Expression levels of let-7 targets in BE(2)C:MYCN cells 
transfected with siCon or siMYCN-3′UTR. (f) Relative let-7 expression in BE2C:MYCN 
cells co-transfected with siCon or siMYCN (3′UTR) siRNA and miRCon or let-7a mimic. A 
16 fold increase in let-7a results in an approximately 8 fold increase in total let-7, due to 
let-7a making up almost half of the total cellular pool (fig. 3c, lower panel) (g) Relative 
expression levels of let-7 targets in siCon and siMYCN cells transfected with let-7a mimic. 
(data represents one round of mRNA-seq, ***p<0.001, one-tailed Wilcoxon test, GSE81497, 
see Source Data F3).
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Extended Data 10. Neuroblastoma patient and ENCODE data
(a) Detail of the incidence of chromosome 3p21 and 11q23 loss and MYCN amplification as 
determined by analysis of the indicated retrospective chromosomal aberration studies on 
neuroblastoma. (b) List of the ENCODE sRNA-seq samples analyzed (with associated GEO 
Accession numbers) for the relative expression of mature let-7 in figure 5c. (c) List of let-7 
family host transcripts, transcript class, and let-7 location within the transcript. (d) List of 
the ENCODE mRNA-seq samples analyzed (with associated UCSC Submission ID 
numbers) for the relative expression of let-7 host-transcripts in figure 5d. (e) Relative 
expression of let-7a2, let-7f2, and let-7g host genes by microarray in MYCN-amplified and 
non-amplified neuroblastoma. ACTB shown as control. (*p<0.05, **p<0.01, ***p<0.001, 
unpaired t-test, n = 643, Source Data ED). (f) Schematic showing the several mechanisms 
that impair let-7 biogenesis and function in neuroblastoma (chromosome images created at: 
http://www.ncbi.nlm.nih.gov/genome/tools/gdp/).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The LIN28B/let-7/MYCN axis is intact in neuroblastoma
(a) pcDNA3.1:MYCN constructs. (b) Immunoblot for indicated proteins in non-MYCN-
amplified neuroblastoma cells transfected indicated constructs. (c) Immunoblot for indicated 
proteins in GFP or LIN28B expressing cells transfected as in b. (d) qPCR analysis of let-7a 
levels and immunoblot for MYCN in MYCN-amplified cells transfected with control or 
let-7a mimic dose curve (data representative of 3 independent experiments). For gel source 
data, see Supplemental Figures.
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Figure 2. LIN28B is dispensable in human MYCN amplified neuroblastoma cells
(a,b) Immunoblot for MYCN and LIN28B in cells infected with indicated Cas9-gRNA 
lentivirus. For gel source data, see Supplemental Figures. (c,d) Cell growth analysis of cells 
infected as in b, c. (BrdU incorporation). (e,f) qPCR analysis of relative let-7 expression in 
cells from b, and c respectively. Fold change relative to GFP gRNA controls. (n = 3 
independent experiments, mean + standard error of the mean (s.e.m.) shown).
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Figure 3. MYCN mRNA is an amplified competing endogenous RNA (aceRNA) for let-7
(a) Let-7-target-site-pool contribution of the top 50 targets. Arrows indicate top two 
contributors (n = 3 biologic replicates, GSE81498, see Source Data F3). (b) Box and 
whisker plot of top 14,000 expressed mRNAs from dataset described in a. MYCN 
expression rank marked by asterisk (GSE81498, see Source Data F3). (c) Top panel: MYCN 
transcripts and let-7-sites-provided per cell as determined by the dataset from a. (mean + 
standard deviation from the mean (s.d.) shown, GSE81498, see Source Data F3) Lower 
panel: let-7 copies per cell as determined sRNA-seq (n = 3 biologic replicates, GSE81499, 
see Source Data F3). (d) Top Panel: Relative fluorescence ratio in BE(2)C cells co-
transected with indicated constructs small RNAs. Bottom panel: Relative fluorescence ratio 
in cells co-transfected with indicated constructs and small RNAs. Mean of four independent 
experiments plus s.e.m. (*p<0.05 relative to E.V., unpaired t-test) (e) mRNA-seq reads 
mapping to the MYCN locus in BE(2)C:MYCN cells transfected with indicated siRNAs. 
Blue and red boxes indicate MYCN ORF and UTRs, respectively. Triangles mark reduction 
of MYCN mRNA untranslated regions. (f) Expression levels of mRNAs with 1, 2, or 3+ 
let-7 sites (left panel) or with 1 or 2+ 8mer let-7 sites (right panel) in siCon and siMYCN 
cells (data represents one round of mRNA-seq, ***p<0.0001, one-tailed Wilcoxon test). (g) 
Relative expression of mRNAs with 1, 2, or 3+ let-7 sites (left panel) or with 1 or 2+ 8mer 
let-7 sites (right panel) in siCon and siMYCN cells co-transfected with let-7a. Values 
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relative miRCon. (data represents one round of mRNA-seq, *p<0.05, **p<0.001, 
***p<0.001 vs. siCon, one-tailed Wilcoxon test, GSE81497, see Source Data F3).
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Figure 4. Let-7a2 and let-7g are commonly lost in neuroblastoma
(a) Scaled Venn diagram assembled from Pugh, et. al., (2013) detailing relative incidence 
and intersection of chromosome 11q and 3p loss and MYCN amplification.. (b) Genetic 
locations of 12 distinct let-7 family members. Green triangles let-7 loci. Red boxes indicate 
the SRO for these deletions. (Images created at: http://www.ncbi.nlm.nih.gov/genome/tools/
gdp/).
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Figure 5. The MYCN aceRNA model predicts let-7 chromosomal loss patterns in neuroblastoma
(a) let-7 and miR-103a loci CN heat map based on aCGH relative fluorescence ratios of 
tumor vs. germline. (Source Data F5). (b) CN loss incidence for let-7 and miR-103a from 
dataset in a (upper panel). Average CN change for the two miRNA families (lower panel). 
(*p<0.05, **p<0.01, ***p<0.001 amp vs. non for each locus, unpaired t-test, Source Data 
F5) (c) Mature let-7 expression based on ENCODE sRNA-seq data. (*p<0.05, **p<0.01, 
***p<0.001 vs. let-7c, Wilcoxon test, Source Data F5) (d) Relative let-7 host transcript 
levels based on ENCODE mRNA-seq data. (*p<0.05, **p<0.01 vs. let-7c, Wilcoxon test, 
Source Data 3) (e) Relative expression of indicated host genes in MYCN-amplified and non-
amplified neuroblastoma. β-TUB shown as control. (n = 498, **p<0.01, ***p<0.001, 
unpaired t-test, Source Data F5). (f) Overall survival curves of neuroblastoma patients in 
non-amplified (top panel), and MYCN-amplified (bottom panel) neuroblastoma. p-values 
determined by Mantel-Cox test (Source Data F5).
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